Stay updated on GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial

Sign up to get notified when there's something new on the GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Latest revision updated to v3.4.3, replacing the previous v3.4.2 in the page history.
    Difference
    0.1%
    Check dated 2026-03-11T18:00:26.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Revision v3.4.2 was added to the history; the prior funding notice and v3.4.1 entry were removed.
    Difference
    0.8%
    Check dated 2026-02-11T02:33:31.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Added a site-wide notice regarding government funding delays and updated the revision from v3.4.0 to v3.4.1.
    Difference
    0.8%
    Check dated 2026-02-03T23:44:29.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Added a 'Show glossary' option, color-coded highlights for additions (green) and deletions (red) in the study history, and a revision note showing v3.4.0 replacing v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    1%
    Check dated 2026-01-27T20:55:01.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4; no changes to study data or page content, and to avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-20T15:34:50.000Z thumbnail image
  8. Check
    70 days ago
    Change Detected
    Summary
    The record now shows Active, not recruiting and an updated title reflecting Relapse/Refractory AML. It also adds new sections including IPDSharing, Contacts/Locations, Study Design, Conditions, Study Description, Oversight, Sponsor/Collaborators, and Recruitment Status.
    Difference
    2%
    Check dated 2026-01-06T03:21:04.000Z thumbnail image

Stay in the know with updates to GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial page.